- NYSE: RCL is on the rise on the day that the US beings vaccinating its population against COVID-19.
- A return to normal would allow Royal Caribbean Cruises to bring elderly customers onboard.
- Investors are shrugging off the firm's financial woes.
A small clinic in Long Island, New York, administered the first coronavirus vaccine in the US and own in Miami Florida, management at Royal Caribbean Cruises (NYSE: RCL) is also cheering. The Pfizer/BioNTech jab will probably be joined by other immunizations in bringing the world's richest country to controlling the disease that has killed nearly 300,000 people.
Most of the cruise sector's clientele are elderly people that are more likely to develop serious COVID-19 illness and have a higher chance to pass away. Moreover, many of those opting for a sedentary vacation on the seas suffer from additional health issues, increasing their risk. If everything goes to plan, most of these high-risk individuals – which have priority – will be immune to covid within several months.
The grand effort has begun on Monday after the Food and Drugs Administration (FDA) approved the drug on Friday. The regulator will likely grant Moderna's authorization as early as the end of this week.
The upbeat news comes after a bruising year to cruising and Royal Caribbean in particular.
RCL stock forecast
NYSE: RCL is trading up by 0.79% on Monday, changing hands at $76.94, a far cry from the 52-week high of $135.32. Cruising ships were seen as floating contagion spaces after the Diamond Princess was moored at the Tokyo bay early in the year. More recently, a cruise ship that went for a sail out of Singapore had to halt its journey after a client became a covid patient.
Moreover, and contrary to rival Carnival, RCL has financial issues. Alongside Norweigan Cruise Line, another competitor, Royal was put on credit watch by S&P Global Ratings. The renowned credit rating firm cited extensions of cruising suspensions as the primary reason for the warning.
Overall, there is room for recovery, but the seas may be stormy until vaccines prompt enough clients to book a cruise.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD clings to gains above 1.0750 after US data
EUR/USD manages to hold in positive territory above 1.0750 despite retreating from the fresh multi-week high it set above 1.0800 earlier in the day. The US Dollar struggles to find demand following the weaker-than-expected NFP data.
GBP/USD declines below 1.2550 following NFP-inspired upsurge
GBP/USD struggles to preserve its bullish momentum and trades below 1.2550 in the American session. Earlier in the day, the disappointing April jobs report from the US triggered a USD selloff and allowed the pair to reach multi-week highs above 1.2600.
Gold struggles to hold above $2,300 despite falling US yields
Gold stays on the back foot below $2,300 in the American session on Friday. The benchmark 10-year US Treasury bond yield stays in negative territory below 4.6% after weak US data but the improving risk mood doesn't allow XAU/USD to gain traction.
Bitcoin Weekly Forecast: Should you buy BTC here? Premium
Bitcoin (BTC) price shows signs of a potential reversal but lacks confirmation, which has divided the investor community into two – those who are buying the dips and those who are expecting a further correction.
Week ahead – BoE and RBA decisions headline a calm week
Bank of England meets on Thursday, unlikely to signal rate cuts. Reserve Bank of Australia could maintain a higher-for-longer stance. Elsewhere, Bank of Japan releases summary of opinions.